Source-based drug interaction information. Detailed information is available with page access.<\/p>","protected":true},"excerpt":{"rendered":"
Source-based drug interaction information. Detailed information is available with page access.<\/p>","protected":true},"ism_preview":{"drugs":[{"title":"Darolutamide","url":"https:\/\/www.ortaakarsu.net\/?page_id=12343","facts":[{"label":"Active ingredient \/ generic name","value":"darolutamide"},{"label":"ATC code","value":"L02BB06"},{"label":"Administration route","value":"Oral"}]},{"title":"Enzalutamide","url":"https:\/\/www.ortaakarsu.net\/?page_id=12351","facts":[{"label":"Active ingredient \/ generic name","value":"enzalutamide"},{"label":"ATC code","value":"L02BB04"},{"label":"Administration route","value":"Oral"}]}],"record":[{"label":"Record type","value":"Published interaction record"},{"label":"Source record version","value":"EMA Nubeqa SmPC; retrieved 2026-11-02; SmPC 4.5"}],"sources":[{"label":"NUBEQA official product information","url":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/nubeqa-epar-product-information_en.pdf"},{"label":"Enzalutamide EMA product information: enzyme-induction evidence","url":"https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/xtandi-epar-product-information_en.pdf"}],"reviewed_at":"2026-11-04"},"ism_access":{"required":true,"resource_key":"pair:29642","available":true}}